Research

Hormonal

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces body weight (exceeding 20% in some contexts) and improves glycemic control (HbA1c) in patients with Type 2 Diabetes and Obesity when administered via subcutaneous injection once weekly.

Tirzepatide is a once-weekly subcutaneous injection approved for Type 2 Diabetes and Obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to improve insulin sensitivity and reduce appetite. Clinical trials show it leads to significant weight loss (often >20%) and better blood sugar control than some existing drugs like semaglutide. Common side effects like nausea are usually temporary and managed by starting with a low dose and increasing slowly. It is not a standalone cure but works best with lifestyle changes.

GoodSupportsHIGH confidence
Tirzepatide... can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more than 20% and improving lipid metabolism... Subcutaneous administration once a week is adequate, as it possesses a half-life of about 5 days
Vivek P. Chavda et al. · Molecules · 2022

Why this rating

Based on a mini-review citing Phase 1-3 clinical trials (SURPASS series) and FDA approval.

Source

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review

Vivek P. Chavda et al. · Molecules · 2022

DOI 10.3390/molecules27134315

narrative_reviewCited 189×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →